(Israel21c) Abigail Klein Leichman - Because bladder cancer has a high rate of recurrence, patients must be monitored invasively every few months after initial treatment. Nucleix of Rehovot has developed an inexpensive, noninvasive urine test to help urologists better monitor bladder-cancer patients. Next in the product pipeline for Nucleix is diagnostic screening to detect lung cancer in blood samples.
2017-04-21 00:00:00Full ArticleBACK Visit the Daily Alert Archive